Art Pappas is a Managing Partner at Pappas Capital, which over the past two decades, has managed $450 million in capital and invested in more than 70 life science companies through its flagship Pappas Ventures business unit, as well as its Specialized Fund Management business unit. He has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life sciences companies. Prior to founding Pappas in 1994, Art held senior-level leadership positions at several multinational pharmaceutical companies, including Glaxo Holdings plc and Abbott International Ltd., where he was responsible for the development, licensing and launch of a number of global products. Previously, he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. Art has a MBA from Xavier University and a BS in Biology from Ohio State University. He is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center.
Art is a member of the board of directors of the National Venture Capital Association and the North Carolina Biotechnology Center, where he was a past chair. He is also a member of the board of directors of the Medical University of South Carolina Foundation for Research Development, the board of trustees of The Wistar Institute, a National Cancer Institute center, the board of advisors of the Duke Cancer Institute, the advisory board of the BioExec Institute, the CEO Roundtable on Cancer and BayHelix, an organization of global life science community leaders. He previously served on the boards of Afferent Pharmaceuticals (acquired by Merck in 2016), Chimerix, Quintiles Transnational, TYRX (acquired by Medtronic in 2013), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx and Embrex (acquired by Pfizer in 2006). Art also served as a board observer for Plexxikon (sold to Daiichi Sankyo in 2011).